Mariner
JSPR icon

Mariner’s Jasper Therapeutics JSPR Stock Holding History

Mariner’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-406
Closed -$29K – 3681
2025
Q3 		$29K Sell
406
-444
-52% -$40.4K ﹤0.01% 3490
2025
Q2 		$142K Sell
850
-190
-18% -$28.1K ﹤0.01% 3160
2025
Q1 		$134K Sell
1,040
-186
-15% -$37.1K ﹤0.01% 3128
2024
Q4 		$787K Sell
1,226
-181
-13% -$113K ﹤0.01% 1824
2024
Q3 		$794K Sell
1,407
-171
-11% -$102K ﹤0.01% 1780
2024
Q2 		$1.07M Sell
1,578
-183
-10% -$132K ﹤0.01% 1459
2024
Q1 		$1.55M Sell
1,761
-207
-11% -$110K ﹤0.01% 1238
2023
Q4 		$466K Sell
1,968
-208
-10% -$41.9K ﹤0.01% 1982
2023
Q3 		$457K Sell
2,176
-207
-9% -$75.8K ﹤0.01% 1843
2023
Q2 		$980K Buy
+2,383
New +$1.06M ﹤0.01% 1324

Other funds holding JSPR

Velan Capital Investment Management
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Rock Springs Capital Management
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Mariner's JSPR Position: Q4 2025 in Review

Mariner sold out of Jasper Therapeutics (JSPR) in Q4 2025, closing a stake of 406 shares — an estimated $29K sold.

Mariner first reported a position in JSPR in Q2 2023 and held it in 10 quarters. The position peaked at $1.55M in Q1 2024. 52 funds tracked by Wall St. Rank hold JSPR as of Q4 2025.

  • Mariner reported no remaining Jasper Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Mariner sold 406 Jasper Therapeutics shares in Q4 2025, an estimated $29K.
  • Mariner first reported a position in Jasper Therapeutics in Q2 2023 and held it in 10 quarters.
  • Mariner's Jasper Therapeutics position peaked at $1.55M in Q1 2024.
  • 52 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2025.

Based on Mariner's 13F filing for Q4 2025, filed 13 Feb 2026.